A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00609141

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:40.920442+00:00

Published At

2014-06-19T00:00:00+00:00

Record Updated At

2014-06-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2014-06-19"

protocolSection.identificationModule.nctId

"NCT00609141"

protocolSection.identificationModule.officialTitle

"A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
• Unspecified Childhood Solid Tumor, Protocol Specific (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.